Australian PET imaging agents market to rise at 2% CAGR through 2033

Its growth is attributed to the prevalence of prostate cancer.

Australia’s positron emission tomography (PET) imaging agents market is projected to rise at a compound annual growth rate of 2% through 2033, said GlobalData.

The sector’s expansion is attributed to the prevalence of prostate cancer, which stands as one of the most diagnosed cancers in the country.

These agents, particularly those targeting prostate-specific membrane antigen, provide effective means to detect and monitor the disease at a molecular level.

Meanwhile, their use is expanding beyond prostate cancer with technological advancements in hybrid imaging systems, such as PET/CT and PET/MRI, driving the market.

"PET imaging agents are becoming the essential components in modern medical diagnostics, setting new standards in clinical practice," Aditi Dakshesh Parikh, Medical Devices Analyst at GlobalData, said.

Australia represents approximately 15% of the Asia Pacific nuclear imaging agents market in 2024.

Follow the link s for more news on

hospital diagnostics

medical devices

report

Also Read

New ADHD outreach clinic to launch in Moree, Australia

Burjeel Holdings launches specialised network of day surgery centres

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

I want to download the media kit